Zhifei Bio's flu vaccine enters phase I/II trials

Chongqing Zhifei Biological Products (SZSE:300122) announced that its subsidiary, Zhifei Longkema, has commenced Phase I/II clinical trials for its quadrivalent influenza virus split vaccine (ZFA02 adjuvant). The trials will assess the vaccine's safety, tolerability, and immunogenicity. The vaccine is designed to stimulate humoral and cellular immune responses against influenza virus hemagglutinin (HA) antigens, aiming to prevent influenza caused by vaccine-related strains. Currently, no adjuvanted influenza vaccines are officially approved in China, although Seqirus has an adjuvanted influenza vaccine approved and used overseas. The trials represent the application of the company's new adjuvant technology platform and are part of its efforts to innovate and accelerate scientific research. The company stated that successful development would enhance its product portfolio and market competitiveness.